Table 2 Cellular immunogenicity outcomes in evaluable analysis populations by vaccine regimen.
BNT162b2 | CoronaVac | ||||
|---|---|---|---|---|---|
Adolescents | Adolescents | Adults | Adolescents | Adults | |
1 dose | 2 doses | 2 doses | 2 doses | 2 doses | |
T cell responses | |||||
S-specific T cell responses on flow cytometry | |||||
N | 58 | 56 | 47 | 60 | 36 |
GM % IFN-γ+CD4+ T cells | 0.014% | 0.041% | 0.033% | 0.023% | 0.021% |
(95% CI) | (0.009-0.021%) | (0.028-0.06%) | (0.020-0.056%) | (0.015-0.036%) | (0.011-0.039%) |
% positive (>/ = cut-off at 0.005%) | 62.1%, P = 0.21 | 83.9%, P = 0.33 | 74.5% | 70.0%, P = 0.38 | 61.1% |
GM % IL-2+CD4+ T cells | 0.023% | 0.032% | 0.028% | 0.015% | 0.015% |
(95% CI) | (0.016-0.033%) | (0.023-0.045%) | (0.018-0.044%) | (0.011-0.020%) | (0.010-0.024%) |
% positive (>/ = cut-off at 0.005%) | 74.1%, P = 0.82 | 85.7%, P = 0.31 | 76.6% | 73.3%, P = 0.82 | 69.4% |
GM % IFN-γ+CD8+ T cells | 0.009% | 0.018% | 0.013% | 0.014% | 0.015% |
(95% CI) | (0.006-0.014%) | (0.011-0.028%) | (0.008-0.024%) | (0.009-0.023%) | (0.007-0.029%) |
% positive (>/ = cut-off at 0.005%) | 41.4%, P = 0.69 | 57.1%, P = 0.33 | 46.8% | 48.3%, P = 0.83 | 44.4% |
GM % IL-2+CD8+ T cells | 0.005% | 0.005% | 0.007% | 0.006% | 0.007% |
(95% CI) | (0.004-0.007%) | (0.004-0.007%) | (0.005-0.010%) | (0.005-0.008%) | (0.004-0.010%) |
% positive (>/ = cut-off at 0.005%) | 32.8%, P = 0.11 | 44.6%, P = 0.70 | 48.9% | 48.3%, P = 0.67 | 41.7% |
Total S, N and M-specific T cell responses on flow cytometry | |||||
N | / | / | / | 60 | 36 |
GM % IFN-γ+CD4+ T cells | / | / | / | 0.058% | 0.068% |
(95% CI) | (0.041-0.083%) | (0.041-0.113%) | |||
% positive (>/ = cut-off at 0.01%) | / | / | / | 83.3%, P = 0.59 | 77.8% |
GM % IL-2+CD4+ T cells | / | / | / | 0.039% | 0.040% |
(95% CI) | (0.030-0.052%) | (0.027-0.057%) | |||
% positive (>/ = cut-off at 0.01%) | / | / | / | 83.3%, P = 0.59 | 77.8% |
GM % IFN-γ+CD8+ T cells | / | / | / | 0.050% | 0.041% |
(95% CI) | (0.033-0.077%) | (0.023-0.071%) | |||
% positive (>/ = cut-off at 0.01%) | / | / | / | 65.0%, P = 0.52 | 58.3% |
GM % IL-2+CD8+ T cells | / | / | / | 0.017% | 0.020% |
(95% CI) | (0.014-0.022%) | (0.014-0.027%) | |||
% positive (>/ = cut-off at 0.01%) | / | / | / | 58.3%, P > 0.9999 | 58.3% |
N-specific T cell responses on flow cytometry | |||||
N | / | / | / | 60 | 36 |
GM % IFN-γ+CD4+ T cells | / | / | / | 0.011% | 0.010% |
(95% CI) | (0.008-0.017%) | (0.006-0.016%) | |||
% positive (>/ = cut-off at 0.005%) | / | / | / | 55.0%, P = 0.68 | 50.0% |
GM % IL-2+CD4+ T cells | / | / | / | 0.013% | 0.012% |
(95% CI) | (0.009-0.018%) | (0.008-0.018%) | |||
% positive (>/ = cut-off at 0.005%) | / | / | / | 66.7%, P > 0.9999 | 66.7% |
GM % IFN-γ+CD8+ T cells | / | / | / | 0.008% | 0.006% |
(95% CI) | (0.005-0.012%) | (0.003-0.010%) | |||
% positive (>/ = cut-off at 0.005%) | / | / | / | 31.7%, P = 0.64 | 25.0% |
GM % IL-2+CD8+ T cells | / | / | / | 0.004% | 0.004% |
(95% CI) | (0.003-0.005%) | (0.003-0.006%) | |||
% positive (>/ = cut-off at 0.005%) | / | / | / | 28.3%, P = 0.81 | 25.0% |
M-specific T cell responses on flow cytometry | |||||
N | / | / | / | 60 | 36 |
GM % IFN-γ+CD4+ T cells | / | / | / | 0.007% | 0.009% |
(95% CI) | (0.005-0.010%) | (0.005-0.016%) | |||
% positive (>/ = cut-off at 0.005%) | / | / | / | 36.7%, P = 0.67 | 41.7% |
GM % IL-2+CD4+ T cells | / | / | / | 0.006% | 0.006% |
(95% CI) | (0.004-0.007%) | (0.004-0.009%) | |||
% positive (>/ = cut-off at 0.005%) | / | / | / | 46.7%, P > 0.9999 | 47.2% |
GM % IFN-γ+CD8+ T cells | / | / | / | 0.006% | 0.005% |
(95% CI) | (0.004-0.009%) | (0.003-0.008%) | |||
% positive (>/ = cut-off at 0.005%) | / | / | / | 25.0%, P = 0.62 | 19.4% |
GM % IL-2+CD8+ T cells | / | / | / | 0.004% | 0.004% |
(95% CI) | (0.003-0.005%) | (0.003-0.006%) | |||
% positive (>/ = cut-off at 0.005%) | / | / | / | 23.3%, P > 0.9999 | 25.0% |
